Mirum Pharmaceuticals clinches Bluejay acquisition to lead in rare liver disease
Mirum Pharmaceuticals (NASDAQ:MIRM) announced the successful closing of its acquisition of Bluejay Therapeutics, a move that significantly broadens its rare disease pipeline with a potential first-in-class therapy for chronic hepatitis delta virus (HDV).










-640x358.jpg&w=3840&q=75)